Telotristat etiprate + Placebo-matching telotristat etiprate
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoid Syndrome
Conditions
Carcinoid Syndrome
Trial Timeline
Jan 8, 2013 → Mar 21, 2016
NCT ID
NCT01677910About Telotristat etiprate + Placebo-matching telotristat etiprate
Telotristat etiprate + Placebo-matching telotristat etiprate is a phase 3 stage product being developed by Lexicon Pharmaceuticals for Carcinoid Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01677910. Target conditions include Carcinoid Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01677910 | Phase 3 | Completed |
Competing Products
20 competing products in Carcinoid Syndrome